SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (403)3/7/2000 11:29:00 AM
From: seminole  Respond to of 1169
 
Richard

IMO, treating ovarian patients that fail taxol and the pt drugs is very difficult. It would take one hell of a drug to do well in this kind of study.

richard



To: scaram(o)uche who wrote (403)3/7/2000 8:05:00 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 1169
 
Refractory ovarian/breast cancer seams to be *reasonable* target for INCEL/Taxol registrational PIII trial(s). So far +12% and +15% overall response rate isn't earth-shaking but do live bit of the hope that combination my work for specific pts.

However, BCHE do not think the some. They have their own MDR candidate and it may explain their position on INCEL.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News